Introduction of digital therapeutics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Ji Sun | - |
dc.contributor.author | Wasden, Chris | - |
dc.contributor.author | Han, Doug Hyun | - |
dc.date.accessioned | 2021-09-29T01:40:16Z | - |
dc.date.available | 2021-09-29T01:40:16Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 0169-2607 | - |
dc.identifier.issn | 1872-7565 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/49999 | - |
dc.description.abstract | Background and objectives: Digital therapeutics are an emerging type of medical therapy and are defined as evidence-based therapeutic interventions for patients by means of qualified software programs to pre-vent, manage, or treat medical conditions. Today, digital therapeutics products are on the market or under development for a wide range of medical conditions such as diabetes, oncology treatment management, and neuropsychiatric disorders including anxiety disorder, depression, and substance use disorder. Digital therapeutics can be more flexible than other treatment methods to address patients' individual needs. Methods and results: The advantages of digital therapeutics fall in line with market demand; thus, the digital therapeutics market is expanding globally, focusing on advanced medical markets. There are many digital therapeutics products such as Sleepio for insomnia, Daylight for anxiety, Livongo and Omada prod-ucts for diabetes, pre-diabetes, hypertension, etc. None of these are cleared by the Food and Drug Admin-istration (FDA), but all are commercially available through health insurance or employers. The EU, includ-ing Germany, and a number of Asian countries, including Korea, Japan, and China, are also introducing policies for the regulation of new fields and digital therapeutics. Conclusions: The adoption of digital therapeutics is intricate and often involves various interests in nu-merous fields, decision-making processes, and individual or organizational value judgments. For digital therapeutics to be thoroughly introduced into real life, technical aspects must be supported, and an ap-proach that considers users must be further investigated. (c) 2021 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.title | Introduction of digital therapeutics | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.cmpb.2021.106319 | - |
dc.identifier.bibliographicCitation | COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, v.209 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000695214600013 | - |
dc.identifier.scopusid | 2-s2.0-85111821465 | - |
dc.citation.title | COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE | - |
dc.citation.volume | 209 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 아일랜드 | - |
dc.subject.keywordAuthor | Digital therapeutics | - |
dc.subject.keywordAuthor | Medical software programs | - |
dc.subject.keywordAuthor | Decision-making process | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | INFORMATION | - |
dc.subject.keywordPlus | CARE | - |
dc.relation.journalResearchArea | Computer Science | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Medical Informatics | - |
dc.relation.journalWebOfScienceCategory | Computer Science, Interdisciplinary Applications | - |
dc.relation.journalWebOfScienceCategory | Computer Science, Theory & Methods | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Medical Informatics | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.